Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Variants & evidence
7,614 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 Fusion2 | ||||||||
| Chemotherapy + ImatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID12615A pediatric patient had a hematopathologic diagnosis of B-ALL determined through bone marrow aspirate analysis. The patient had a hemoglobin level of 3 g/dL, severe neutropenia, and a normal platelet … (full text at CIViC) PMID 38749501 · Booth et al., 2025 · Open in CIViC | civic |
| Dasatinib + ImatinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11120IL3 indépendant Ba/F3 cells transduced with ZMIZ1-ABL1 driver fusion were treated with dasatinib. ZMIZ1-ABL1 cells had IC50 of 1-2 nM, whereas cells transduced with the driver PAX5-JAK2 were not respo… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| FGFR1 Fusion1 | ||||||||
| Midostaurin | Myeloproliferative NeoplasmCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1104A t(8;13)(p11;q12) patient with ZNF198-FGFR1-induced progressive myeloproliferative disorder was treated with PKC412. Radiographic studies performed 3 months after initiation of therapy revealed marke… (full text at CIViC) PMID 15448205 · Chen et al., 2004 · Open in CIViC | civic |
| FGFR1 Fusion + FGFR1 Fusion + FGFR1 Translocation + FGFR1 Fusion + FGFR1 Fusion2 | ||||||||
| Pemigatinib | Lymphoid Leukemia | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12241In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… (full text at CIViC) | civic |
| 〃 | Lymphoma | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12242In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… (full text at CIViC) | civic |
| FLT3 Fusion1 | ||||||||
| (diagnostic) | Myeloproliferative NeoplasmCURATED_BROADER | Diagnostic | C | Supports Positive | 4 | submitted | EID13104This study reported two cases of myeloproliferative neoplasm with eosinophilia harboring a ZMYM2::FLT3 fusion, which was cytogenetically cryptic and resulted from an approximately 8-Mb inversion. Case… (full text at CIViC) PMID 28751768 · Jawhar et al., 2017 · Open in CIViC | civic |
| ZNF217 Overexpression4 | ||||||||
| (prognostic) | Malignant Ovarian Neoplasm | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12207ZNF217 was overexpressed in 60% of ovarian tumour samples (26/44) as demonstrated by immunohistochemistry (IHC). Patients with ZNF217 expression had significantly shorter disease-free survival compare… (full text at CIViC) PMID 25031722 · Li et al., 2014 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Prognostic | D | Supports Poor Outcome | 3 | submitted | EID12208ZNF217 overexpression is linked to reduced survival across multiple breast cancer subtypes. A meta-analysis of relapse-free survival across nine studies involving 858 patients revealed that higher ZNF… (full text at CIViC) PMID 22728437 · Littlepage et al., 2012 · Open in CIViC | civic |
| Triciribine | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | ||||
| JAK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7706This study included 1389 cases of high-risk pediatric B-ALL, out of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on the… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| ZNF292 Mutation1 | ||||||||
| (oncogenic) | Diffuse Large B-Cell LymphomaCURATED_BROADER | Oncogenic | E | Supports Oncogenicity | 3 | submitted | EID12002This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC | civic |
| JAK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7999In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The ZNF430-JAK2 fusion is rare; in this study inv… (full text at CIViC) PMID 27870571 · Roberts et al., 2017 · Open in CIViC | civic |
| ZRSR2 MUTATION1 | ||||||||
| (diagnostic) | Acute Myeloid LeukemiaCURATED_BROADER | Diagnostic | B | Supports Positive | 2 | submitted | EID7466ZRSR2 is part of the spliceosome. Mutation in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 was >95% specific for the diagnosis of secondary-AML PMID 25550361 · Lindsley et al., 2015 · Open in CIViC | civic |
Data updated 18 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| submitted |
EID12209Triciribine inhibits ZNF217-driven tumour growth and signalling both in vivo and in vitro. In mouse models, triciribine reduced tumour burden and levels of phospho-AKT and phospho-MAPK, while increasi… (full text at CIViC) PMID 22728437 · Littlepage et al., 2012 · Open in CIViC |
| civic |
| 〃 | Osteosarcoma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12210In an orthotopic mouse model of osteosarcoma (OSA), triciribine (TCN) treatment significantly reduces tumour growth and weight in both SJSA-1 and HOS cell line injections, with 5.4- and 3.0-fold reduc… (full text at CIViC) PMID 32999043 · Smeester et al., 2020 · Open in CIViC | civic |